表紙
市場調查報告書

高度神經膠質瘤:流行病學預測(至2030年)

High-Grade Glioma - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948139
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
高度神經膠質瘤:流行病學預測(至2030年) High-Grade Glioma - Epidemiology Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

2017年,七個主要國家(美國,德國,西班牙,意大利,法國,英國和日本)的高級神經膠質瘤(HGG)市場達到32,444例。

本報告調查並分析了全球高級神經膠質瘤(HGG)治療藥物市場,並提供了有關七個主要國家的疾病背景,流行病學和市場趨勢的系統信息。

內容

第1章主要注意事項

第2章高級神經膠質瘤概述

第3章高級神經膠質瘤(HGG):疾病的背景和概述

  • 簡介
  • 類型
  • 原因
  • 風險因素
  • 體徵和症狀
  • 病理生理學
  • HGG患者生物標誌物
  • 診斷
    • 神經系統檢查
    • 血管造影
    • 磁共振成像(MRI)和計算機斷層掃瞄(CT)
    • 灌注MRI
    • MR光譜
    • 組織學診斷
    • 手術活檢
  • 神經膠質瘤的診斷算法 歐洲神經腫瘤學會(EANO)對成人星形膠質細胞和少突膠質細胞瘤的診斷指南

第4章流行病學和患者人數

  • 主要發現

第7章高級神經膠質瘤的總患病率

第5章按國家分類的高級神經膠質瘤(HGG)流行病學

  • 美國
    • 假設和依據
    • 美國高級別神經膠質瘤的總患病率
    • 在美國瀰漫性中線神經膠質瘤的總患病率
    • 在美國,具有H3K27突變的瀰漫性中線神經膠質瘤的總患病率
    • 美國按性別分列的高級神經膠質瘤發病率
  • 5個歐盟國家
  • 德國
    • 德國高級腦膠質瘤患者總數
    • 德國瀰漫性中線神經膠質瘤患者總數
    • 德國患有H3K27突變的瀰漫性中線神經膠質瘤的總患病率
    • 德國高級神經膠質瘤的性別發病率
  • 法國
  • 意大利
  • 西班牙
  • 英國
    • 英國高級別膠質瘤患者總數
    • 英國瀰漫性中線神經膠質瘤患者總數
    • 在英國存在H3K27突變的瀰漫性中線神經膠質瘤總患病率
    • 英國按性別分列的高級神經膠質瘤發病率
  • 日本

第24章附錄

  • 參考
  • 報告調查方法

第25章:DelveInsight服務內容

第26章免責聲明

第27章:關於Delve Insight

目錄
Product Code: DIEI0985

DelveInsight's 'High-grade Glioma (HGG) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted High-grade Glioma (HGG) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

High-grade Glioma (HGG) Understanding

Highly malignant or high-grade gliomas (HGG) are tumors of the central nervous system (CNS), wherein high-grade means that the glioma is growing rapidly. They are solid tumors arising from transformed cells of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumors, thereby differentiating them from malignant tumors of other organs that have spread (metastasized) to the CNS. HGG can occur in different parts of the central nervous system, and they can affect children of any age. The tumors most often originate in the supratentorial region of the brain and the brain stem; HGG originating from the supratentorial region are often called supratentorial HGG.

A glioma is a name for tumors of the glial cells, which are the supporting cells of the nervous system. Gliomas are classified based on the type of glial cells involved in the tumor as well as tumor's genetic features. The World Health Organization (WHO) classification of CNS tumors is the most widely accepted system for classifying CNS tumors and was based on the histological characteristics of the tumor. As per the WHO classification system, grade III tumours (i.e. anaplastic astrocytoma, anaplastic oligoastrocytoma and anaplastic oligodendroglioma), grade IV tumours (i.e. Glioblastoma) and diffuse midline gliomas (DMG), H3K27M-mutant are considered to be high-grade gliomas (HGG).

HGGs account for approximately 15-20 % of CNS tumors in children and adolescents. They appear in all age groups, yet, children aged younger than three years are rarely affected. Each year, about 60-80 children and adolescents younger than 15 years are newly diagnosed with an HGG, which corresponds to an incidence rate of 5-10 new diagnoses/1, 000, 000 children/year. HGGs affect both boys and girls almost equally, and its symptoms vary depending on which area of the brain is affected.

The initial diagnostic procedures for a young patient presenting with a suspected CNS tumor at a childhood cancer center include another assessment of the patient's history, a thorough physical/neurological exam and imaging diagnostic, such as magnetic resonance imaging (MRI). However, diagnostic procedures required for a definite and complete diagnosis of HGG involves:

  • Imaging studies require a whole-brain scan, which can be done using MRI or CT. Both tests provide a very detailed image of the brain. Usually, a contrast dye is also given through a vein for the CT or MRI to visualize the brain better. However, a CT or MRI cannot determine for sure if a mass is a brain tumor.
  • The only way to determine the type of tumor with certainty is for a neurosurgeon to remove a piece of the tumor during surgery (resection), which can then be studied under a microscope.
  • A biopsy may be done without a larger surgery; this approach is preferred if the tumor is located within a critical area of the brain or if the patient is too sick for surgery. In these circumstances, a procedure called a stereotactic needle biopsy is used to take a sample of the tumor by inserting a needle through the skull into the brain itself.

Treatment for HGG usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since HGGs develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient's brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispeciality approach can cause several side effects, steroids are often provided as another essential part of HGG treatment, used to help alleviate the side effects of other therapies.

High-grade Glioma (HGG) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of High-grade Glioma (HGG), Total Incident Population of Diffuse Midline Glioma (DMG), Total Incident Population of Diffuse Midline Glioma With H3K27 Mutation and Gender-specific Incidence of High-grade Glioma (HGG) in the 7 MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2030.

High-grade Glioma (HGG) Detailed Epidemiology Segmentation

  • The total incident population of High-grade Glioma in the 7 major markets was found to be 32,444 in 2017. In case of High-grade Glioma patients in the United States, the incident cases were estimated to be 16,295 in 2017.
  • There are three main types of High-grade Gliomas that are considered in this report: Anaplastic Astrocytoma (WHO Grade III tumor), Glioblastoma (WHO Grade IV tumor) and Diffuse Midline Glioma (WHO Grade IV tumor), where the majority of cases were found to be of glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
  • Incidence of Diffuse Midline Glioma with H3K27 Mutation has been considered in this report as well. The highest incidence of H3K27 mutants were found in pediatric population which was estimated to be 303 in 2017 in the United States. However, the incident population of H3K27 mutants in adult population was found to be 204 in 2017 in the United States.
  • Japan accounted for 2,519 incident cases of High-grade Glioma in 2017, which is expected to increase in the forecast period 2020-2030.

Scope of the Report:

  • The report covers the descriptive overview of High-grade Glioma (HGG), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of High-grade Glioma (HGG).
  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of High-grade Glioma (HGG) and Severity-based Diagnosed Prevalent Population of High-grade Glioma (HGG).

Report Highlights:

  • Eleven Year Forecast of High-grade Glioma (HGG)
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of High-grade Glioma (HGG)
  • The report contains Gender-specific prevalence of HGG in the 7MM, wherein males are found to suffer more as compared to females.
  • Report also covers Incident Population of Diffuse Midline Glioma, including both adult and pediatric population of HGG.
  • DelveInsight has also estimated Incident Population of Diffuse Midline Glioma With H3K27 Mutation, including both adult and pediatric population of HGG. It was found that H3K27 mutation is more prevalent in adult DMG patients than in pediatric DMG patients.
  • The most commonly used chemotherapeutic drug for treating HGG in the United States is temozolomide (Temodar/Temodal; TMZ). It is generally used in combination with radiation therapy.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of High-grade Glioma (HGG)?
  • What is the historical High-grade Glioma (HGG) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of High-grade Glioma (HGG) at the 7 MM level?
  • What will be the growth opportunities across the 7 MM with respect to the patient population pertaining to High-grade Glioma (HGG)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of High-grade Glioma (HGG) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7 MM during the forecast period (2020-2030)?

Reasons to buy:

The High-grade Glioma (HGG) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7 MM High-grade Glioma (HGG) market.
  • Quantify patient share distribution in the 7 MM for High-grade Glioma (HGG).
  • The High-grade Glioma (HGG) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The High-grade Glioma (HGG) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 High -grade Glioma Epidem Overview at a Glance

3 High -grade Glioma (HGG): Disease Background and Overview

  • 3.1 Introduction
  • 3.2 Types
  • 3.3 Causes
  • 3.4 Risk Factors
  • 3.5 Signs and Symptoms
  • 3.6 Pathophysiology
  • 3.7 Biomarkers for patients with HGG
  • 3.8 Diagnosis
    • 3.8.1 Neurological Exams
    • 3.8.2 Angiograms
    • 3.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)
    • 3.8.4 Perfusion MRI
    • 3.8.5 MR spectroscopy
    • 3.8.6 Histological Diagnosis
    • 3.8.7 Surgical Biopsy
  • 3.9 Diagnostic Algorithm for Gliomas
  • 3.1 Diagnostic Guidelines for Adult Astrocytic and Oligodendroglial Gliomas by the European Association for Neuro-oncology (EANO)

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2

7 MM Total Incident Patient Population of High-grade Glioma

5 Country Wise-Epidemiology of High-grade Glioma (HGG)

  • 5.1 United States
    • 5.1.1 Assumptions and Rationale
    • 5.1.3 Total Incident Population of High-grade Glioma in the United States
    • 5.1.4 Total Incident Population of Diffuse Midline Glioma in the United States
    • 5.1.5 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United States
    • 5.1.6 Gender -specific Incidence of High-grade Glioma in the United States
  • 5.2 EU 5 Countries
    • 5.2.1 Assumptions and Rationale
  • 5.3 Germany
    • 5.3.1 Total Incident Population of High-grade Glioma in Germany
    • 5.3.2 Total Incident Population of Diffuse Midline Glioma in Germany
    • 5.3.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Germany
    • 5.3.4 Gender -specific Incidence of High-grade Glioma in Germany
  • 5.4 France
    • 5.4.1 Total Incident Population of High-grade Glioma in France
    • 5.4.2 Total Incident Population of Diffuse Midline Glioma in France
    • 5.4.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in France
    • 5.4.4 Gender -specific Incidence of High-grade Glioma in France
  • 5.5 Italy
    • 5.5.1 Total Incident Population of High-grade Glioma in Italy
    • 5.5.2 Total Incident Population of Diffuse Midline Glioma in Italy
    • 5.5.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Italy
    • 5.5.4 Gender -specific Incidence of High-grade Glioma in Italy
  • 5.6 Spain
    • 5.6.1 Total Incident Population of High-grade Glioma in Spain
    • 5.6.2 Total Incident Population of Diffuse Midline Glioma in Spain
    • 5.6.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Spain
    • 5.6.4 Gender -specific Incidence of High-grade Glioma in Spain
  • 5.7 United Kingdom
    • 5.7.1 Total Incident Population of High-grade Glioma in the United Kingdom
    • 5.7.2 Total Incident Population of Diffuse Midline Glioma in the United Kingdom
    • 5.7.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United Kingdom
    • 5.7.4 Gender -specific Incidence of High-grade Glioma in the United Kingdom
  • 5.8 Japan
    • 5.8.1 Assumptions and Rationale
    • 5.8.2 Total Incident Population of High-grade Glioma in Japan
    • 5.8.3 Total Incident Population of Diffuse Midline Glioma in Japan
    • 5.8.4 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Japan
    • 5.8.5 Gender -specific Incidence of High-grade Glioma in Japan

24 Appendix

  • 24.1 Bibliography
  • 24.2 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

  • Table 1: Genetic and epigenetic alterations found in DMG
  • Table 2: Gene mutations, gene polymorphism, gene variants possibly implicated in glioma risk
  • Table 3: Medical conditions and relation to glioma risk
  • Table 4: Prognostic Molecular Markers in Gliomas
  • Table 5: Total Incident Patient Population of High-grade Glioma in the 7 MM (2017-2030)
  • Table 6: Total Incident Population of High-grade Glioma in the United States (2017-2030)
  • Table 7: Total Incident Population of Diffuse Midline Glioma in the United States (2017-2030)
  • Table 8: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United States (2017-2030)
  • Table 9: Gender-specific Incidence of High-grade Glioma in the United States (2017-2030)
  • Table 10: Total Incident Population of High-grade Glioma in Germany (2017-2030)
  • Table 11: Total Incident Population of Diffuse Midline Glioma in Germany (2017-2030)
  • Table 12: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Germany (2017-2030)
  • Table 13: Gender-specific Incidence of High-grade Glioma in Germany (2017-2030)
  • Table 14: Total Incident Population of High-grade Glioma in France (2017-2030)
  • Table 15: Total Incident Population of Diffuse Midline Glioma in France (2017-2030)
  • Table 16: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in France (2017-2030)
  • Table 17: Gender-specific Incidence of High-grade Glioma in France (2017-2030)
  • Table 18: Total Incident Population of High-grade Glioma in Italy (2017-2030)
  • Table 19: Total Incident Population of Diffuse Midline Glioma in Italy (2017-2030)
  • Table 20: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Italy (2017-2030)
  • Table 21: Gender-specific Incidence of High-grade Glioma in Italy (2017-2030)
  • Table 22: Total Incident Population of High-grade Glioma in Spain (2017-2030)
  • Table 23: Total Incident Population of Diffuse Midline Glioma in Spain (2017-2030)
  • Table 24: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Spain (2017-2030)
  • Table 25: Gender-specific Incidence of High-grade Glioma in Spain (2017-2030)
  • Table 26: Total Incident Population of High-grade Glioma in the United Kingdom (2017-2030)
  • Table 27: Total Incident Population of Diffuse Midline Glioma in the United Kingdom (2017-2030)
  • Table 28: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United Kingdom (2017-2030)
  • Table 29: Gender-specific Incidence of High-grade Glioma in the United Kingdom (2017-2030)
  • Table 30: Total Incident Population of High-grade Glioma in Japan (2017-2030)
  • Table 31: Total Incident Population of Diffuse Midline Glioma in Japan (2017-2030)
  • Table 32: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Japan (2017-2030)
  • Table 33: Gender-specific Incidence of High-grade Glioma in Japan (2017-2030)

List of Figures

  • Figure 1: Causes of HGG
  • Figure 2: Symptoms of HGG
  • Figure 3: Diagnostic Algorithm for Gliomas
  • Figure 4: Total Incident Patient Population of High-grade Glioma in the 7 MM (2017-2030)
  • Figure 5: Total Incident Population of High-grade Glioma in the United States (2017-2030)
  • Figure 6: Total Incident Population of Diffuse Midline Glioma in the United States (2017-2030)
  • Figure 7: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the US (2017-2030)
  • Figure 8: Gender-specific Incidence of High-grade Glioma in the United States (2017-2030)
  • Figure 9: Total Incident Population of High-grade Glioma in Germany (2017-2030)
  • Figure 10: Total Incident Population of Diffuse Midline Glioma in Germany (2017-2030)
  • Figure 11: Total Incident Population of DMG with H3K27 Mutation in Germany (2017-2030)
  • Figure 12: Gender-specific Incidence of High-grade Glioma in Germany (2017-2030)
  • Figure 13: Total Incident Population of High-grade Glioma in France (2017-2030)
  • Figure 14: Total Incident Population of Diffuse Midline Glioma in France (2017-2030)
  • Figure 15: Total Incident Population of DMG with H3K27 Mutation in France (2017-2030)
  • Figure 16: Gender-specific Incidence of High-grade Glioma in France (2017-2030)
  • Figure 17: Total Incident Population of High-grade Glioma in Italy (2017-2030)
  • Figure 18: Total Incident Population of Diffuse Midline Glioma in Italy (2017-2030)
  • Figure 19: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Italy (2017-2030)
  • Figure 20: Gender-specific Incidence of High-grade Glioma in Italy (2017-2030)
  • Figure 21: Total Incident Population of High-grade Glioma in Spain (2017-2030)
  • Figure 22: Total Incident Population of Diffuse Midline Glioma in Spain (2017-2030)
  • Figure 23: Total Incident Population of DMG with H3K27 Mutation in Spain (2017-2030)
  • Figure 24: Gender-specific Incidence of High-grade Glioma in Spain (2017-2030)
  • Figure 25: Total Incident Population of High-grade Glioma in the United Kingdom (2017-2030)
  • Figure 26: Total Incident Population of Diffuse Midline Glioma in the United Kingdom (2017-2030)
  • Figure 27: Total Incident Population of DMG with H3K27 Mutation in the UK (2017-2030)
  • Figure 28: Gender-specific Incidence of High-grade Glioma in the United Kingdom (2017-2030)
  • Figure 29: Total Incident Population of High-grade Glioma in Japan (2017-2030)
  • Figure 30: Total Incident Population of Diffuse Midline Glioma in Japan (2017-2030)
  • Figure 31: Total Incident Population of DMG with H3K27 Mutation in Japan (2017-2030)
  • Figure 32: Gender-specific Incidence of High-grade Glioma in Japan (2017-2030)